SOD1 and amyotrophic lateral sclerosis: The phase 3 VALOR trial (NCT02623699) enrolled 108 patients diagnosed with ALS and confirmed mutations in the SOD1 gene to investigate the clinical benefits of tofersen treatment (randomization ratio of 2:1, 72 patients received the treatment, and 36 patients were assigned in the placebo group)141.